Unable to display view head.php file not found.
 
American Journal of Medicine
 

AHA/ASA 2012 Update: Stroke Prevention in Atrial Fibrillation and the NOACs

The most recent statement regarding anticoagulation prophylaxis for patients with atrial fibrillation comes from the AHA and the American Stroke Association (ASA).[27] Vitamin K antagonists (notably warfarin) and the NOACs (ie, dabigatran, apixaban, and rivaroxaban) are all indicated for prevention of both first and recurrent stroke in patients with nonvalvular atrial fibrillation (Figure 19).  This guideline does not provide any specific basis for choosing between these different therapies.  Camm J. Am J Med 2013; published on-line at http://education.amjmed.com/00000.

References

[27] Furie KL, Goldstein LB, Albers GW, et al; American Heart Association Stroke Council; Council on Quality of Care and Outcomes Research; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:3442-3453.

Unable to display view foot.php file not found.